

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug types best reflects the mechanism of action of pivekimab sunirine?
 - a. FLT3 inhibitor
 - b. IDH1/2 inhibitor
 - c. CD47-targeted antibody
 - d. CD123-targeted antibody-drug conjugate

2. Which of the following drug types best reflects the mechanism of action of ziftomenib?
 - a. FLT3 inhibitor
 - b. IDH1/2 inhibitor
 - c. Menin inhibitor
 - d. CD123-targeted antibody-drug conjugate

3. Revumenib is FDA approved for patients with relapsed/refractory acute leukemia with what genetic change?
 - a. NPM1 mutation
 - b. ASXL1 mutation
 - c. IDH1 mutation
 - d. KMT2A translocation

4. What was the approximate reduction in the risk of death with quizartinib in combination with chemotherapy in patients with newly diagnosed FLT3-positive acute myeloid leukemia (AML) in the Phase III QuANTUM-First trial?
 - a. 5%
 - b. 11%
 - c. 23%
 - d. 46%

5. Which of the following genes is most commonly mutated in AML?
 - a. IDH2
 - b. TP53
 - c. DNMT3A
 - d. FLT3